Literature DB >> 25022659

Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients.

Alice Albu1, Serban Radian, Simona Fica, Carmen Gabriela Barbu.   

Abstract

The aim of the study was to determine whether Romanian polycystic ovary syndrome (PCOS) patients have an increased prevalence of metabolic syndrome (MetS) and to study the involvement of adiposity, insulin resistance and hyperandrogenism in the pathogenesis of MetS in PCOS. A total of 398 PCOS patients and 126 controls were evaluated between January 2006 and December 2012. MetS was defined by National Cholesterol Education Program, Adult Treatment Panel III criteria. Principal component analysis (PCA) was used to analyze the correlations among variables of interest by grouping them in few components, and principal component (PCs) scores were saved and used as independent variables in logistic regression. The prevalence of MetS was higher among patients with PCOS (20.4 %) than in controls (11.1 %, p < 0.05). In PCOS patients, PCA extracted three PCs from the analyzed variables. First PC aggregated variables related to adiposity and insulin resistance, with factor loadings showing strong relationship between these parameters. The second PC included markers of hyperandrogenemia and was best represented by free androgen index (FAI) which correlated strongly and exclusively with this PC. The third component was best represented by hirsutism. Logistic regression analysis revealed that in PCOS patients, the first and the second PCs were independently associated with MetS, whereas the third component was not. Romanian PCOS patients have an increased risk for MetS; adiposity, insulin resistance and hyperandrogenemia, but not hirsutism, are independent predictors of MetS presence. Our data also suggest that insulin resistance is only secondary to increased adiposity and FAI is a good marker of biochemical hyperandrogenism with little influences from the metabolic component.

Entities:  

Mesh:

Year:  2014        PMID: 25022659     DOI: 10.1007/s12020-014-0340-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  40 in total

1.  Age associated differences in prevalence of individual rotterdam criteria and metabolic risk factors during reproductive age in 446 caucasian women with polycystic ovary syndrome.

Authors:  D Glintborg; H Mumm; P Ravn; M Andersen
Journal:  Horm Metab Res       Date:  2012-03-01       Impact factor: 2.936

2.  Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism.

Authors:  Didier Dewailly; Pascal Pigny; Benoît Soudan; Sophie Catteau-Jonard; Christine Decanter; Edouard Poncelet; Alain Duhamel
Journal:  J Clin Endocrinol Metab       Date:  2010-07-07       Impact factor: 5.958

3.  Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome.

Authors:  Edmond P Wickham; Kathryn G Ewens; Richard S Legro; Andrea Dunaif; John E Nestler; Jerome F Strauss
Journal:  J Clin Endocrinol Metab       Date:  2011-01-20       Impact factor: 5.958

4.  The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions.

Authors:  P M Nilsson; G Engström; B Hedblad
Journal:  Diabet Med       Date:  2007-03-22       Impact factor: 4.359

5.  Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers.

Authors:  H L Ching; V Burke; B G A Stuckey
Journal:  Clin Endocrinol (Oxf)       Date:  2007-03       Impact factor: 3.478

Review 6.  Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Lisa J Moran; Marie L Misso; Robert A Wild; Robert J Norman
Journal:  Hum Reprod Update       Date:  2010-02-16       Impact factor: 15.610

7.  Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.

Authors:  A Corbould
Journal:  J Endocrinol       Date:  2007-03       Impact factor: 4.286

8.  Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women.

Authors:  Mark O Goodarzi; Nissar A Shah; Heath J Antoine; Marita Pall; Xiuqing Guo; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2006-07-18       Impact factor: 5.958

Review 9.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

10.  Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome.

Authors:  Thomas M Barber; Stephen J Golding; Christopher Alvey; John A H Wass; Fredrik Karpe; Stephen Franks; Mark I McCarthy
Journal:  J Clin Endocrinol Metab       Date:  2007-12-18       Impact factor: 5.958

View more
  9 in total

1.  Is prolactin the missing link in adipose tissue dysfunction of polycystic ovary syndrome patients?

Authors:  Alice Albu; Suzana Florea; Simona Fica
Journal:  Endocrine       Date:  2015-06-12       Impact factor: 3.633

2.  Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.

Authors:  Anna Krentowska; Agnieszka Łebkowska; Małgorzata Jacewicz-Święcka; Justyna Hryniewicka; Monika Leśniewska; Agnieszka Adamska; Irina Kowalska
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

3.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

4.  Association of Androgen Excess with Glucose Intolerance in Women with Polycystic Ovary Syndrome.

Authors:  Bingjie Zhang; Jing Wang; Shanmei Shen; Jiayi Liu; Jie Sun; Tianwei Gu; Xiao Ye; Dalong Zhu; Yan Bi
Journal:  Biomed Res Int       Date:  2018-03-08       Impact factor: 3.411

5.  Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome.

Authors:  Anja E Sørensen; Pernille B Udesen; Grzegorz Maciag; Julian Geiger; Negar Saliani; Andrzej S Januszewski; Guozhi Jiang; Ronald C Ma; Anandwardhan A Hardikar; Marie Louise M Wissing; Anne Lis M Englund; Louise T Dalgaard
Journal:  Front Med (Lausanne)       Date:  2019-11-01

6.  Are Dietary Indices Associated with Polycystic Ovary Syndrome and Its Phenotypes? A Preliminary Study.

Authors:  Ana Cutillas-Tolín; Julián Jesús Arense-Gonzalo; Jaime Mendiola; Evdochia Adoamnei; Fuensanta Navarro-Lafuente; María Luisa Sánchez-Ferrer; María Teresa Prieto-Sánchez; Ana Carmona-Barnosi; Jesús Vioque; Alberto M Torres-Cantero
Journal:  Nutrients       Date:  2021-01-22       Impact factor: 5.717

7.  Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study.

Authors:  Chun Yuan; Xiaoqiang Liu; Yundong Mao; Feiyang Diao; Yugui Cui; Jiayin Liu
Journal:  J Biomed Res       Date:  2016-04-30

8.  Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden.

Authors:  K Kosidou; C Dalman; L Widman; S Arver; B K Lee; C Magnusson; R M Gardner
Journal:  Mol Psychiatry       Date:  2015-12-08       Impact factor: 15.992

9.  Follicular hyperandrogenism and insulin resistance in polycystic ovary syndrome patients with normal circulating testosterone levels.

Authors:  Andi Li; Lu Zhang; Jiajia Jiang; Nan Yang; Ying Liu; Lingbo Cai; Yugui Cui; Feiyang Diao; Xiao Han; Jiayin Liu; Yujie Sun
Journal:  J Biomed Res       Date:  2017-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.